Kallyope announced that its acute migraine drug elismetrep succeeded in a Phase 2b study and is moving into a Phase 3 program. The mid‑stage result demonstrated the primary efficacy endpoint in acute migraine treatment, prompting the company to scale its clinical plan toward registrational studies. Kallyope’s advancement underscores ongoing investment in non‑opioid, mechanism‑targeted migraine therapies and sets the stage for larger safety and efficacy datasets in the coming 12–18 months.